BioCentury | Jun 3, 2017
Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
BioCentury | Aug 9, 2010
Clinical News

Revlimid lenalidomide: Phase II/III started

Celgene began a double-blind Phase II/III (DLC-001) trial to compare Revlimid vs. a single agent of investigator's choosing. The Phase II portion will stratify 100 patients by non-germinal center B cell (GCB) or GCB phenotype....
BioCentury | Apr 22, 2010
Distillery Therapeutics

Indication: Neurology

...Aneurysm Cyclin M2 (CNNM2); retinoblastoma binding protein 8 (RBBP8); StAR-related lipid transfer domain containing 13 (STARD13...
...In cohorts from Europe and Japan, rs11661542, near RBBP8; rs12413409, in CNNM2; and rs9315204, in STARD13...
BioCentury | Feb 19, 2007
Company News

Avanir Pharmaceuticals management update

Avanir Pharmaceuticals (AVNR), Aliso Viejo, Calif. Business: Infectious, Neurology, Inflammation Hired: Martin Sturgeon as VP and chief accounting officer, formerly interim chief accounting officer and interim corporate controller at DLC Inc. WIR Staff...
Items per page:
1 - 4 of 4